Pfizer and BioNTech's COVID-19 is the top-selling pharmaceutical product ever in a single year, after the company reported it made $36.8 billion in 2021 on the vaccine.
The second-highest pharmaceutical product sales in a single year also came in 2021 for Humira, with $20.7 billion.
"In the early days of the COVID-19 pandemic, we committed to use all of the resources and expertise we had at our disposal to help protect populations globally against this deadly virus," said Dr. Albert Bourla, Pfizer Chairman and CEO.
"We put billions of dollars of capital on the line in pursuit of those goals, not knowing whether those investments would ever pay off."
"These successes have not only made a positive difference in the world, but I believe they have fundamentally changed Pfizer and its culture forever."
Pfizer expects $32 billion of vaccine sales in 2022 and $22 billion in revenue from the company's COVID pill "Paxlovid," Axios reports.
"As I prepare to retire as CFO of Pfizer, I am proud to see that the company is performing better than at any other time during my nearly 15 years here," said Frank D'Amelio, Pfizer CFO and Executive Vice President.
"Today we are issuing guidance for the coming year which, if achieved, would represent the highest level of annual revenues and Adjusted diluted EPS(3) in Pfizer's long history."
"I have never been more confident in the future of Pfizer."
With governments mandating the jabs, what a time to be in Big Pharma!
P.S. Now check out our latest video 👇
